Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation

Ventyx Biosciences ( (VTYX) ) just unveiled an announcement.

On January 7, 2026, Ventyx entered into a merger agreement under which Eli Lilly and Company will acquire Ventyx via a merger of a Lilly subsidiary, with Ventyx becoming a wholly owned subsidiary and its shares converted into $14.00 in cash per share and subsequently delisted from Nasdaq. Supplemental proxy disclosures detail extensive outreach to 16 large biopharmaceutical companies after positive Phase 2 data for VTX3232 in October 2025, the financial analyses by Jefferies and Moelis showing the $14.00 offer exceeds their implied standalone equity value ranges, assumptions about future partnerships and net operating loss utilization, the absence to date of post-merger employment arrangements for executives, early termination on February 11, 2026 of the HSR antitrust waiting period filed on January 23, 2026, and new shareholder litigation in New York challenging the adequacy of merger-related disclosures and seeking to delay or alter the transaction.

The most recent analyst rating on (VTYX) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Ventyx Biosciences stock, see the VTYX Stock Forecast page.

Spark’s Take on VTYX Stock

According to Spark, TipRanks’ AI Analyst, VTYX is a Neutral.

The score is held back primarily by weak fundamentals typical of a development-stage biotech (no revenue, ongoing losses, and negative free cash flow), despite a low-debt balance sheet. Offsetting this, technicals show strong positive momentum with price well above key moving averages, and corporate events are supportive due to the announced all-cash acquisition by Eli Lilly, which reduces standalone business risk and increases visibility on value realization. Valuation remains constrained by losses (negative P/E) and no dividend support.

To see Spark’s full report on VTYX stock, click here.

More about Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies, including VTX3232 for cardiovascular risk reduction and Parkinson’s disease and VTX2735 for recurrent pericarditis. The company targets large indications with significant unmet medical need and pursues global partnerships to commercialize its pipeline assets.

Average Trading Volume: 3,314,377

Technical Sentiment Signal: Buy

Current Market Cap: $1B

For an in-depth examination of VTYX stock, go to TipRanks’ Overview page.